famotidine has been researched along with chlorhexidine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Briggs, JM; Bushman, FD; Carlson, HA; Jorgensen, WL; Lins, RD; Masukawa, KM; McCammon, JA; Rubins, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Brockmöller, J; Dücker, C; Gebauer, L; Jensen, O | 1 |
4 other study(ies) available for famotidine and chlorhexidine
| Article | Year |
|---|---|
Developing a dynamic pharmacophore model for HIV-1 integrase.
Topics: Computer Simulation; Drug Evaluation, Preclinical; HIV Integrase; HIV Integrase Inhibitors; Models, Chemical; Models, Molecular; Protein Conformation; Structure-Activity Relationship | 2000 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
Topics: Biological Transport; Cations; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2 | 2022 |